Harvard Bioscience (HBIO) is off 16% premarket after completing a spin-off of its regenerative medicine device subsidiary.
Harvard Apparatus Regenerative Technology now trades on the Nasdaq under the ticker HART.
HBIO shareholders got one share of HART for every share of HBIO they owned as of October 21.
HBIO now calls itself a "pure-play global developer, manufacturer and marketer of a broad range of tools to advance life science research." (PR)
CEO Jeffrey Duchemin has been appointed President and Director, replacing David Green who is now HART's President.